<unk> , sold under the brand name Zepzelca, is a medication for the treatment of adults with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. The most common side effects include leukopenia, lymphopenia, fatigue, anemia, neutropenia, increased creatinine, increased alanine aminotransferase, increased glucose, thrombocytopenia, nausea, decreased appetite, musculoskeletal pain, decreased albumin, constipation, dyspnea, decreased sodium, increased aspartate aminotransferase, vomiting, cough, decreased magnesium and diarrhea.<unk>  is a synthetic tetrahydropyrrolo 4,3,2-dequinolin-8(1H)-one alkaloid analogue with potential antineoplastic activity.<unk>  covalently binds to residues lying in the minor groove of DNA, which may result in delayed progression through S phase, cell cycle arrest in the G2/M phase and cell death.<unk>  was approved for medical use in the United States in June 2020.
Lurbinectedin
Paclitaxel
Doxorubicin
Busulfan
Lipoplatin
Cabazitaxel
Irinotecan
Capecitabine